Avalo Therapeutics (NASDAQ:AVTX) Upgraded at Wedbush

Wedbush upgraded shares of Avalo Therapeutics (NASDAQ:AVTX) to a strong-buy rating in a report released on Thursday,Zacks.com reports.

Several other equities research analysts also recently weighed in on AVTX. HC Wainwright assumed coverage on shares of Avalo Therapeutics in a research note on Thursday, October 24th. They set a “neutral” rating on the stock. BTIG Research initiated coverage on Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price target on the stock.

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX opened at $8.44 on Thursday. Avalo Therapeutics has a 52-week low of $4.20 and a 52-week high of $34.46. The business’s 50 day moving average is $7.80 and its two-hundred day moving average is $9.39.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. acquired a new stake in shares of Avalo Therapeutics in the 3rd quarter valued at about $9,186,000. Ikarian Capital LLC grew its stake in shares of Avalo Therapeutics by 1,673.0% in the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after purchasing an additional 915,629 shares during the last quarter. Northern Trust Corp acquired a new position in shares of Avalo Therapeutics in the fourth quarter valued at approximately $168,000. Velan Capital Investment Management LP purchased a new stake in shares of Avalo Therapeutics during the fourth quarter worth approximately $817,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after purchasing an additional 3,754 shares during the period. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.